Therefore, for the long‐term management of acute COVID‐19 infections and persistent symptoms (i.e., long COVID) in patients with diabetes, the use of glucose‐lowering medications that do not increase body weight and improve cardiorenal outcomes (such as SGLT‐2 inhibitors and GLP‐1RAs) is recommended, although there is no evidence from long‐term follow‐up.315. This evidence concerns the gene SLC5A2 and diabetes mellitus.